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Abstract
Background: HIV-1 infection is associated with profound dysfunction of myeloid dendritic cells, for reasons that
remain ill-defined. Soluble HLA class I molecules can have important inhibitory effects on T cells and NK cells, but
may also contribute to reduced functional properties of professional antigen-presenting cells. Here, we investigated
the expression of soluble HLA class I isoforms during HIV-1 infection and assessed their functional impact on
antigen-presenting characteristics of dendritic cells.
Results: Soluble HLA class I molecules were highly upregulated in progressive HIV-1 infection as determined by
quantitative Western blots. This was associated with strong increases of intracellular expression of HLA class I
isoforms in dendritic cells and monocytes. Using mixed lymphocyte reactions, we found that soluble HLA class I
molecules effectively inhibited the antigen-presenting properties of dendritic cells, however, there was no
significant influence of HLA class I molecules on the cytokine-secretion properties of these cells. The
immunomodulatory effects of soluble HLA class I molecules were mediated by interactions with inhibitory
myelomonocytic MHC class I receptors from the Leukocyte Immunoglobulin Like Receptor (LILR) family.
Conclusions: During progressive HIV-1 infection, soluble HLA class I molecules can contribute to systemic immune
dysfunction by inhibiting the antigen-presenting properties of myeloid dendritic cells through interactions with
inhibitory myelomonocytic HLA class I receptors.
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Background
HIV-1 infection leads to massive immune activation that
results from direct stimulation of immune cells by HIV-
1 antigens, the release of large amounts of pro-inflam-
matory cytokines, and the systemic circulation of bacter-
ial polysaccharide antigens after translocation from
intestinal mucosal tissues [1]. This immune activation
can cause counter-regulatory activities of inhibitory
components of the immune system, such as increased
recruitment of regulatory T cells [2], upregulation of
inhibitory receptors on antigen-specific T cells [3,4], and
enhanced expression of immunoregulatory receptors on
dendritic cells [5,6]. These mechanisms may in part pro-
tect the host against immune pathology by limiting over
activation of the immune system, but might also contri-
bute to viral persistence by propagating immune dys-
function. Identifying immunomodulatory mechanisms
that contribute to this functional disarray between sti-
mulatory and inhibitory immunological pathways is an
important step in understanding the pathogenesis of
HIV-1 infection.
HLA class I isoforms are heterodimeric molecules that
consist of a 44-kDa polymorphic glycoprotein (a chain)
that is noncovalently associated with the 12-kDa non-
polymorphic b2-microglobulin. These molecules are
expressed on the surface of all human cells and have
important functions for presenting antigenic peptides,
and for priming and maintaining T cell immune
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occur as soluble agents in the serum or plasma [7,8].
These soluble HLA class I molecules can either occur as
intact, 44-kDa HLA class I heavy chains, or as 39-kDa
variants that do not contain a transmembrane domain
a n dr e s u l tf r o ma l t e r n a t i v esplicing [9]. 35-kDa species
of soluble HLA class I isoforms have also been
described and most likely represent proteolytic break-
down products of intact HLA class I heavy chains [10].
These soluble HLA molecules can have important sys-
temic immunoregulatory effects by influencing survival
and apoptosis of antigen-specific T cells and NK cells
through interactions with receptors from the KIR or the
C-type lectin family [11-13]. Leukocyte Immunoglobulin
Like Receptors (LILR) represent an alternative group of
HLA class I receptors that are predominantly expressed
on dendritic cells and monocytes, which, as professional
antigen-presenting cells, have central roles for generat-
ing adaptive immune responses and regulating immune
activation through cytokine secretion [14]. Upon trigger-
ing by HLA molecules, these receptors can influence
functional properties of professional antigen-presenting
cells in an inhibitory or stimulatory fashion, and in this
way importantly influence pathogen-specific immune
defense mechanisms. During HIV-1 infection, the quan-
tity of soluble HLA class I isoforms is increased in the
plasma [15], but how these molecules can specifically
affect the functional characteristics of circulating dendri-
tic cells during HIV-1 infection is unclear at present. In
this study, we show that soluble HLA class I isoforms
can importantly alter the antigen-presenting properties
of dendritic cells through interactions with the inhibi-
tory myelomonocytic MHC class I receptors. These data
i n d i c a t eap r e v i o u s l yu n r e c ognized immunoregulatory
pathway that contributes to immune dysfunction of den-
dritic cells in HIV-1 infection.
Results
To investigate immunoregulatory effects of soluble HLA
class I isoforms in HIV-1 infection, we initially focused
on quantifying the expression of HLA class I molecules
in plasma and PBMC. For this purpose, a group of
patients with chronic progressive HIV-1 infection (n =
14, mean viral load of 28,484 (8,104-449,000) copies/ml,
mean CD4 cell counts of 412.5 (195-1000) cells/ul), a
cohort of HIV-1 elite controllers (n = 14, viral load < 75
copies/ml, mean CD4 cell counts of 630 (188-1134)
cells/μl) and a background population of HIV-1 negative
persons (n = 16), were recruited.
Western blot experiments indicated the presence of an
HLA class I-specific, 44-kDa band in PBMC in study
subjects from all three patient cohorts (Figure 1A/B). In
contrast, Western blot experiments from plasma
revealed a 39-kDa band of HLA class I molecules, which
most likely represents splice variants that are secreted
by cells as soluble molecules and lack a transmembrane
domain [9]. These soluble HLA class I forms were sig-
nificantly more strongly expressed in HIV-1 progressors
than in elite controllers or HIV-1 negative persons (Fig-
ure 1A/B). HLA class I associated b2-microglobulin was
also more strongly expressed in plasma of progressors
as compared to elite controllers or HIV-1 negative per-
sons (Additional File 1).
Since increased levels of soluble HLA class I mole-
cules in progressors may result from secretion by per-
ipheral blood leukcoytes, we assessed intracellular
expression of HLA class I molecules in different subsets
of PBMC from our study cohorts. We observed a signifi-
cant upregulation of intracellular HLA class I molecules
in monocytes and dendritic cells from progressors (Fig-
ure 1C). Surface expression of HLA class I molecules on
dendritic cells and monocytes was also higher in pro-
gressors than in the reference cohorts, but these differ-
ences were less pronounced than intracellular HLA class
I expression (Figure 1D). Despite the fact that HIV-1 is
known to downregulate HLA class I expression [16], we
did not observe differences between the surface or intra-
cellular expression of HLA class I molecules on T cells
from the different study cohorts (data not shown), likely
because the proportion of HIV-1 infected cells among
all T lymphocytes in vivo is very low. Overall, these data
suggest that secretion of soluble HLA class I molecules
from dendritic cells and monocytes contributes to
higher levels of soluble plasma HLA class I isoforms
during progressive HIV-1 infection.
To investigate functional effects of soluble MHC class
I isoforms, we focused on how these molecules can
affect the stimulatory characteristics of myeloid dendri-
tic cells which have key roles for the generation of adap-
tive immune responses. For this purpose, we tested the
antigen-presenting properties of monocyte-derived den-
dritic cells (MDDC) in the presence of plasma from
three study cohorts, using mixed lymphocyte reactions.
Briefly, MDDC derived from identical donors were incu-
bated for 30 minutes with respective plasma samples,
washed aggressively, and co-cultured with CFSE-labeled
allogeneic T cells from an HIV-1 negative study subject.
Using flow cytometry assays, > 99% of the MDDC
expressed the dendritic cell surface markers HLA-DR
and CD11c, and HLA class I expression was detectable
on > 98% of these cells (Additional File 2). In compari-
son to MDDC treated with plasma from HIV-1 negative
persons or elite controllers, MDDC exposed to plasma
from HIV-1 progressors had significantly reduced abil-
ities to expand allogeneic T cells; this was true both for
allogeneic CD4 and CD8 T cell responses.
To determine which plasma components in progres-
sors inhibit the stimulatory properties of MDDC, we
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Figure 1 Increased expression of soluble HLA class I molecules in progressive HIV-1 infection. (A-B): Western blots reflecting HLA class I
expression in the plasma and in PBMC of persons with progressive HIV-1 infection, elite controllers and HIV-1 negative individuals. (A) shows
representative data from a given patient from each study cohort; (B) demonstrates cumulative data from indicated patient numbers. (C-D):
Expression of intracellular (C) and membrane-bound (D) HLA class I molecules in monocytes and dendritic cells from the three study cohorts.
Huang et al. Retrovirology 2012, 9:11
http://www.retrovirology.com/content/9/1/11
Page 3 of 8used monoclonal antibodies to deplete HLA class I iso-
forms from the plasma; this procedure selectively
removed approximately 90% of human MHC class I
molecules (Additional File 3). Moreover, expression of
membrane-bound HLA class I molecules on MDDC was
not affected by this procedure, and therefore did not
influence the experimental outcome. These experiments
showed that MDDC exposed to HLA class I-devoid
plasma from progressors had significantly higher stimu-
latory properties compared to MDDC exposed to HLA-
class I containing plasma from progressors. In contrast,
no difference was observed in MDDC function following
exposure to HLA class I-deficient vs. HLA class I-profi-
cient plasma from HIV-1 elite controllers or HIV-1
negative persons (Figure 2A). Moreover, differences
between allogeneic CD4 T cell proliferation were no
longer visible after stimulation with MDDC exposed to
HLA class I-depleted plasma form the three study
cohorts (Figure 2A). We also observed a strong inverse
correlation between the proliferative activity of allogenic
T cells and corresponding quantities of soluble HLA
class I molecules in the plasma (Figure 2B). Together,
these results indicate that soluble HLA class I isoforms
represent a plasma component that decreases stimula-
tory properties of MDDC during progressive HIV-1
infection.
To further investigate immunoregulatory effects of solu-
ble HLA class I molecules on dendritic cells, we ana-
lyzed cytokine secretion properties and surface
expression of costimulatory molecules of MDDC follow-
ing exposure to full or HLA class I-depleted plasma
from persons with progressive disease. We observed that
depletion of HLA class I molecules from plasma
resulted in increased expression of the costimulatory
molecules CD80, CD86, and CD83 on MDDC; this is
consistent with an inhibitory effect of soluble HLA class
I molecules on the expression intensity of co-stimulatory
molecules on MDDC (Figure 3). In contrast, secretion of
TNF-a, IL-6 and IL-12p70 was not different in MDDC
exposed either to full or HLA class I depleted plasma
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Figure 2 Soluble HLA class I molecules inhibit antigen-presenting properties of MDDC.( A - B ) :S o l u b l eH L Ac l a s sIm o l e c u l e sb l o c k
allostimulatory activities of MDDC. MDDC were stimulated with plasma from HIV-1 progressors, elite controllers or HIV-1 negative persons with
or without prior depletion of soluble HLA class I molecules. Subsequently, MDDC were mixed with allogeneic T cells. Data reflect proportions of
proliferative allogeneic T cells (A) and correlations between proliferative allogeneic T cell responses and corresponding quantities of soluble HLA
class I isoforms in the plasma (B).
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Page 4 of 8(data not shown), indicating that soluble HLA class I
isotypes do not play a major role for regulating cytokine
secretion characteristics of MDDC.
To explore mechanisms of how soluble HLA class I
isoforms can mechanistically reduce stimulatory proper-
ties of MDDC, we focused on their interactions with
inhibitory myelomonocytic MHC class I receptors from
the LILR family that are constitutively expressed on
dendritic cells, and upregulated during chronic progres-
sive infection [5,6]. LILRB2 is a prominent member of
the LILR family that can induce powerful suppression of
dendritic cells following recognition of membrane-
bound [17] and soluble HLA heavy chains [18]; the sur-
face expression of this receptor on dendritic cells is
strongly upregulated in persons with progressive or
non-progressive HIV-1 infection (Additional File 4). As
shown in Figure 4A, blockade of the LILR binding sites
within soluble HLA class I molecules by use of soluble
recombinant LILRB2 proteins increased functional anti-
gen-presenting properties of MDDC, while a control
protein (Gluthatione-S-Transferase) has no similar
effects; this suggests that inhibitory effects of soluble
HLA class I molecules on MDDC are predominantly
mediated by interactions with LILRB2. To further inves-
tigate this, we analyzed stimulatory properties of MDDC
in the presence or absence of HLA class I-depleted
plasma after targeted siRNA-mediated knock-out of
LILRB2 in MDDC. Electroporation with LILRB2-specific
siRNA highly effectively reduced LILRB2 surface expres-
sion on MDDC (Additional File 5). Our experiments
demonstrated that following siRNA-mediated downregu-
lation of LILRB2 in MDDC, plasma from HIV-1 pro-
gressors was no longer able to reduce the stimulatory
effects of MDDC. Moreover, after silencing of LILRB2
expression in MDDC, no difference was detectable
between the allostimulatory activities of MDDC exposed
to HLA class I-proficient or -deficient plasma from pro-
gressors, further indicating that soluble HLA class I
molecules inhibit functional antigen-presenting proper-
ties of dendritic cells via binding to LILRB2 (Figure 4B).
Discussion
As the most effective professional antigen-presenting
cells, dendritic cells play critical roles for generating,
maintaining and fine-tuning T-, B- and NK-cell
mediated immune responses against HIV-1. In persons
with natural control of HIV-1 infection, myeloid dendri-
tic cells have superior antigen-presenting properties [6],
while severe dysfunction of these cells has been reported
in advanced stages of HIV-1 infection [17,19]. This sug-
gests that dendritic cell function can importantly influ-
ence clinical HIV-1 disease outcomes, but mechanistic
pathways regulating the functional activity of these cells
in HIV-1 infection remain poorly defined. In the present
study, we demonstrate that soluble HLA class I mole-
cules serve as systemic inhibitors of the functional prop-
erties of dendritic cells by interacting with inhibitory
myelomonocytic MHC class I molecules from the LILR
family. This indicates that in addition to their well-
documented role for inhibiting various effector cell
populations of the immune system [11-13], soluble HLA
class I isoforms can contribute to progressive immune
dysfunction in advanced HIV-1 infection by inhibiting
professional antigen-presenting cells.
Multiple soluble factors have been identified that lead
to systemic perturbations of immune system during
HIV-1 infection. Most dominantly, such soluble factors
include pro-inflammatory cytokines which are secreted
in larger amounts by dendritic cells, monocytes, T cells
and B cells during progressive HIV-1 infection [20,21].
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isoforms in the plasma of persons with progressive HIV-
1 infection remains to be determined in detail, but
increased intracellular accumulation of HLA class I iso-
forms in monocytes and dendritic cells suggests an
autocrine effect by which release of these molecules
from professional antigen-presenting cells autoregulates
the functional properties of the secreting cells.
Obviously, such a view does not exclude paracrine
effects of soluble HLA class I molecules on other cell
types localized in the surrounding microenvironment.
Moreover, it is likely that soluble HLA class I molecules
represent only one of multiple additional plasma com-
ponents that regulate functional characteristics of den-
dritic cells; other intact or proteolytic fragments of
plasma proteins may also have an important influence
on dendritic cell functions, and remained to be investi-
gated in future studies.
In this study, we found that soluble HLA class I mole-
cules inhibit allostimulatory functions of DC through
interactions with LILRB2, although cytokine secretion of
dendritic cells remained unaffected by interactions
between LILRB2 and soluble HLA class I molecules.
This contrasts to the effects of soluble HLA-G mole-
cules, which can alter both antigen-presenting properties
and secretion of pro-inflammatory cytokines in dendritic
cells [22]. Together, these results suggest that individual
functional properties of dendritic cells are differentially
affected by triggering of LILRB2 through either classical
or non-classical soluble HLA class I molecules. Gener-
ally, LILRB2 is highly upregulated on DC during chronic
progressive HIV-1 infection [5] and seems to play an
important role for inducing a tolerogenic profile of den-
dritic cells in the setting of immune tolerance after solid
organ transplantation [23] and during pregnancy [24].
In previous studies, tolerogenic effects of LILRB2 were
attributed to interactions with membrane-bound HLA
class I molecules; however, the results presented here
suggest that binding of soluble HLA class I isotypes can
similarly trigger LILRB2-mediated tolerogenic effects in
DC. This is well in line with the recent description of
strong interactions between LILRB2 and soluble HLA
class I heavy chains [18].
Specific HLA class I alleles are among the best predic-
tors of spontaneous HIV-1 disease progression [25,26],
and it will be important to determine whether associa-
tions between specific HLA class I isoforms and HIV-1
disease outcomes may be at least in part attributable to
immunoregulatory effects of soluble HLA class I mole-
cules on dendritic cells. Previous work has indeed
shown that dendritic cell dysfunction resulting from
interactions between specific membrane-bound HLA
class I molecules and MHC class I receptors from the
LILR family can critically determine HIV-1 disease pro-
gression [18,27]. Moreover, HLA allele-specific interac-
tions between soluble HLA class I heavy chains and
immunoregulatory receptors from the LILR family have
recently been demonstrated using a bead-based assay in
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Page 6 of 8a cell-free system [18]. Future investigations will be
necessary to compare functional immunoregulatory
effects of individual soluble HLA class I isoforms asso-
ciated with distinct HIV-1 disease outcomes.
Conclusions
Our data suggest that high levels of circulating soluble
HLA class I molecules during progressive HIV-1 infec-
tion contribute to HIV-1-associated immune dysfunc-
tion by reducing stimulatory properties of myeloid
dendritic cells. In this way, soluble HLA class I mole-
cules may exert important immunoregulatory effects
that propagate immune deficiency and viral persistence
during HIV-1 infection.
Material and Methods
Study subjects
Study participants were recruited at the Massachusetts
General Hospital after giving written consent according
to protocols approved by the local Institutional Review
Board. HIV-1 patients were not taking antiretroviral
therapy at the time of study participation.
Western blots
Equal amounts of plasma were subjected to SDS-PAGE
(Tris-Glycine 4-20% gels, Invitrogen), electroblotted and
incubated with antibodies specific for HLA class I (clone
T25.99 recognizing the HLA class I alpha3 domain [28],
kindly provided by Dr. Soldano Ferrone, University of
Pittsburg), b2-microglobulin (clone BBM.1, Santa Cruz
Biotechnology) or b-actin (Abcam), followed by visuali-
zation with HRP-labeled secondary antibodies and ECL
detection reactions (Amersham Biosciences).
Flow cytometric analysis of HLA-ABC expression
PBMCs were incubated with monoclonal antibodies
against HLA-A, -B -C isoforms (clone W6/32, specific
for HLA class I/b2-microglobulin complexes), CD14,
HLA-DR, CD11c and a cocktail of lineage antibodies
(CD3, CD14, CD16, CD19, CD56) for 20 min at room
temperature. For intracellular detection of HLA-class I
isoforms, cells were stained with surface antibodies,
fixed and permeabilized using a commercial kit (Caltag),
followed by intracellular staining with biotinylated HLA
class I-specific antibodies (clone W6/32) and streptavi-
din-PE. Cells were analyzed on an LSRII (BD Bios-
ciences) instrument.
Depletion of soluble HLA-ABC
Plasma samples were incubated with biotinylated HLA
class I antibody (clone W6/32) for 1 h at room tempera-
ture, followed by immunomagnetic depletion of HLA
class I molecules using anti-biotin magnetic beads
(Invitrogen).
Preparation of Monocyte-derived dendritic cells (MDDC)
Freshly isolated PBMC were incubated for 60 min at 37°
C to adhere monocytes. Adherent monocytes were pro-
pagated for 5d in the presence of 50 ng/ml GM-CSF
(CellGenix). Immature myelomonocytic cells were then
incubated with either full plasma or HLA-class I-
depleted plasma at 37°C for 30 min, followed by aggres-
sive washes. In some experiments, recombinant LILRB2
protein (R&D Systems) was added to full plasma for 1 h
before adding to the MDDC. When indicated, MDDC
were electroporated with LILRB2-specific siRNA as
described before [6]. MDDC were matured for 16 h
using a previously described cytokine cocktail containing
IL-1b, TNF-a, PGE-2, and IL-6 [6].
Dendritic cell functional assays
Matured MDDC were mixed with CFSE-labeled allo-
geneic T cells from identical, HIV-1 negative donors.
After 6 consecutive days of culture, cells were stained
with monoclonal CD4+ and CD8+ antibodies and ana-
lyzed by flow cytometry. For the detection of cytokine
secretion in MDDC, immatured cells were stimulated
with 5 μg/ml TLR7/8 ligands CL097 (InvivoGen, San
Diego, CA) for 20 h in the presence of Brefeldin A.
After fixation and permeabilization, intracellular cyto-
kine staining was performed using antibodies against IL-
6, IL-12p70, TNF-a.
Statistics
Data were expressed using Box- and Whisker plots,
indicating the median, minimum, maximum and the
25
th and 75
th percentiles. Statistical comparisons were
made using Mann Whitney U tests or Wilcoxon rank
sum tests, as appropriate.
Additional material
Additional File 1: Western-blot-based detection of b2-microglobulin
in the plasma from HIV-1 progressors, elite controllers and HIV-1
negative persons.
Additional File 2: Phenotypic characteristics of MDDC used for
mixed lymphocyte reactions. Flow cytometry dot plots indicate the
gating strategy used for identifying MDDC, the proportion of MDDC
expressing the dendritic cell markers CD11c and HLA-DR and the
proportion of MDDC expressing HLA class I molecules.
Additional File 3: Efficacy of antibody-mediated depletion of
soluble HLA class I molecules from plasma. Data demonstrate
western blot-based detection of soluble class I molecules from plasma
before (left panel) and after (middle panel) antibody-mediated depletion.
Right panel reflects western blot of HLA class I molecules isolated from
plasma during depletion procedure.
Additional File 4: Surface expression of LILRB2 on peripheral blood
dendritic cells in HIV-1 elite controllers, HIV-1 progressors and HIV-
1 negative control subjects.
Additional File 5: Efficacy of si-RNA mediated silencing of LILRB2 in
MDDC. Data indicate flow cytometric detection of LILRB2 on cell surface
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control siRNA. One representative example is shown.
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